Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(19 sites)
United States
Dana Farber Cancer Institute, Boston, Massachusetts Vanderbilt Ingram Cancer Center, Nashville, Tennessee Australia
Southern Oncology Clinical Research Unit, Adelaide Breast Cancer Research Centre - WA, Perth Blacktown Hospital, Sydney South Korea
CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do Catholic University of Korea St. Vincent's Hospital, Suwon, Gyeonggi-do Ajou University Hospital, Suwon, Gyeonggi-do Gyeongsang National University Hospital, Jinju, Gyeongsangnam-do Chungbuk National University Hospital, Cheongju-si, North Chungcheong Gachon Gil University Medical Center, Incheon Korea University Anam Hospital, Seoul Seoul National University Hospital, Seoul Severance Hospital, Yonsei University Health System, Seoul Asan Medical Center, Seoul Samsung Medical Center, Seoul The Catholic University of Korea, St. Mary's hospital, Seoul Ulsan University Hospital, Ulsan